company background image
A085660 logo

ChabiotechLtd KOSDAQ:A085660 Stock Report

Last Price

₩14.86k

Market Cap

₩831.8b

7D

-3.8%

1Y

-26.3%

Updated

21 Dec, 2024

Data

Company Financials

Chabiotech Co.,Ltd.

KOSDAQ:A085660 Stock Report

Market Cap: ₩831.8b

A085660 Stock Overview

A bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. More details

A085660 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Chabiotech Co.,Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ChabiotechLtd
Historical stock prices
Current Share Price₩14,860.00
52 Week High₩21,000.00
52 Week Low₩13,350.00
Beta0.19
1 Month Change-2.24%
3 Month Change-15.33%
1 Year Change-26.25%
3 Year Change-21.79%
5 Year Change4.28%
Change since IPO99.10%

Recent News & Updates

Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Nov 12
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Aug 07
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Recent updates

Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Nov 12
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?

Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Aug 07
Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business

Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

Mar 01
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?

If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

Jan 25
If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%

The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About

Dec 21
The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About

Shareholder Returns

A085660KR HealthcareKR Market
7D-3.8%-4.8%-3.7%
1Y-26.3%-22.0%-10.4%

Return vs Industry: A085660 underperformed the KR Healthcare industry which returned -22% over the past year.

Return vs Market: A085660 underperformed the KR Market which returned -10.4% over the past year.

Price Volatility

Is A085660's price volatile compared to industry and market?
A085660 volatility
A085660 Average Weekly Movement5.2%
Healthcare Industry Average Movement9.2%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.7%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A085660 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A085660's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002292Hoon Oh Sangwww.chabio.com

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.

Chabiotech Co.,Ltd. Fundamentals Summary

How do ChabiotechLtd's earnings and revenue compare to its market cap?
A085660 fundamental statistics
Market cap₩831.77b
Earnings (TTM)-₩2.60b
Revenue (TTM)₩1.01t

0.8x

P/S Ratio

-319.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A085660 income statement (TTM)
Revenue₩1.01t
Cost of Revenue₩749.63b
Gross Profit₩260.17b
Other Expenses₩262.77b
Earnings-₩2.60b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-46.49
Gross Margin25.76%
Net Profit Margin-0.26%
Debt/Equity Ratio77.6%

How did A085660 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 00:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chabiotech Co.,Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Jung-In LeeKorea Investment & Securities Co., Ltd.